Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HITIt is the first and only potent,…
6-month commercial pilot demonstrated increasing demand among prescribersExpansion plan includes doubling the number of sales reps, a new GoodRx partnership,…
isupartob sodium product picture Product picture of isupatob sodium (formally known as M6229), which is a treatment in clinical development…
Restructuring Supports RYTELO® U.S. Commercial Strategy and Investment in Clinical Development Expected to Reduce 2026 Projected Operating Expenses FOSTER CITY,…
EMBOLD data to serve as basis of efficacy and safety following discussion with the FDABOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE)…
Oral presentation of ALG-055009 in vivo nonclinical data showcases synergistic fat mass loss in combination with incretin receptor agonists SOUTH…
Phase 1 Clinical Trial Met All Primary and Secondary Endpoints and Demonstrated Positive Safety, Pharmacokinetics, and Mechanistic ValidationClinical Data Build…
Study examines the safety and early efficacy of an oncolytic virus via a single intravenous doseSAN DIEGO, Dec. 11, 2025…
Antigen spreading was evaluated in a subset of Phase 2 patients to assess the ability of ELI-002 7P to broaden…
CNSide Diagnostics now licensed in 48 U.S. States covering over 90% of the U.S. populationHOUSTON, Dec. 11, 2025 (GLOBE NEWSWIRE)…